Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.

First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.

Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer. 

Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.

AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.